Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools

1997 • 38,984 citations

Hepatitis C Virus Infection

2001 • 2,979 citations

Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C

2004 • 2,888 citations

Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor Telaprevir

2007 • 620 citations

Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society–USA Panel

2003 • 524 citations

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

2007 • 383 citations

Characterization of Resistance to Non-obligate Chain-terminating Ribonucleoside Analogs That Inhibit Hepatitis C Virus Replication in Vitro

2003 • 321 citations

Whole-Genome Sequence Assembly for Mammalian Genomes: Arachne 2

2003 • 313 citations

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034

2006 • 237 citations

Natural Prevalence of Hepatitis C Virus Variants with Decreased Sensitivity to NS3·4A Protease Inhibitors in Treatment‐Naive Subjects

2008 • 213 citations

Should Resistance Testing Be Performed for Treatment-Naive HIV-Infected Patients? A Cost-Effectiveness Analysis

2005 • 193 citations

Mechanismof Action and Antiviral Activity of Benzimidazole-Based AllostericInhibitors of the Hepatitis C Virus RNA-Dependent RNAPolymerase

2003 • 189 citations

Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy

2003 • 173 citations

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

2008 • 166 citations

Mutations Conferring Resistance to a Potent Hepatitis C Virus Serine Protease Inhibitor In Vitro

2004 • 164 citations

Viral Determinants of Resistance to Treatment in Patients with Hepatitis C

2007 • 163 citations

Identification of a Ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy

2003 • 130 citations

Characterization of resistance mutations against HCV ketoamide protease inhibitors

2008 • 129 citations

In vitro selected Con1 subgenomic replicons resistant to 2′-C-Methyl-Cytidine or to R1479 show lack of cross resistance

2006 • 128 citations

Hemophilia Growth and Development Study

1993 • 125 citations

Mutations Conferring Resistance to a Hepatitis C Virus (HCV) RNA-Dependent RNA Polymerase Inhibitor Alone or in Combination with an HCV Serine Protease Inhibitor In Vitro

2005 • 120 citations

Replication Fitness and NS5B Drug Sensitivity of Diverse Hepatitis C Virus Isolates Characterized by Using a Transient Replication Assay

2005 • 118 citations

Mutation Rate of the Hepatitis C Virus NS5B in Patients Undergoing Treatment With Ribavirin Monotherapy

2007 • 107 citations

Mutations Conferring Resistance to SCH6, a Novel Hepatitis C Virus NS3/4A Protease Inhibitor

2005 • 104 citations

Viral Sequence Evolution in Acute Hepatitis C Virus Infection

2007 • 104 citations

Relative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon System

2007 • 101 citations

Phenotypic Characterization of Resistant Val ³⁶ Variants of Hepatitis C Virus NS3-4A Serine Protease

2007 • 95 citations

Ribavirin Resistance in Hepatitis C Virus Replicon-Containing Cell Lines Conferred by Changes in the Cell Line or Mutations in the Replicon RNA

2005 • 85 citations

Cohort Profile: The Swiss Hepatitis C Cohort Study (SCCS)

2007 • 71 citations

Preventing and Managing Antiretroviral Drug Resistance

2004 • 69 citations

Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient

2007 • 67 citations

Activity of a Potent Hepatitis C Virus Polymerase Inhibitor in the Chimpanzee Model

2007 • 55 citations

In Vitro Resistance Study of AG-021541, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase

2007 • 46 citations

Selection of Replicon Variants Resistant to ACH-806, a Novel Hepatitis C Virus Inhibitor with No Cross-Resistance to NS3 Protease and NS5B Polymerase Inhibitors

2008 • 45 citations

Evolution of Resistant M414T Mutants among Hepatitis C Virus Replicon Cells Treated with Polymerase Inhibitor A-782759

2007 • 36 citations

Review article: novel therapeutic options for chronic hepatitis C

2008 • 26 citations

843 NATURAL PREVALENCE OF HCV VARIANTS WITH DECREASED SUSCEPTIBILITY TO NS3-4A PROTEASE INHIBITORS IN TREATMENT-NAIVE SUBJECTS

2008 • 9 citations

Sequence variation of NS3 and NS4A in hepatitis C virus (HCV) replicons following exposure to ITMN-191 concentrations likely to encompass those achieved in human liver following clinical dosing

2009 • 7 citations

Novel therapeutic options for chronic hepatitis C

2009 • 3 citations